Diagnostic Group, PATH, 2201 Westlake Ave, Suite 200, Seattle, WA, 98121, USA.
ISGlobal, Barcelona Institute for Global Health, Hospital Clínic-Universitat de Barcelona, Carrer Rosselló 153 (CEK Building), 08036, Barcelona, Spain.
Malar J. 2022 Jun 7;21(1):176. doi: 10.1186/s12936-022-04203-9.
Immunoassay platforms that simultaneously detect malaria antigens including histidine-rich protein 2 (HRP2)/HRP3 and Plasmodium lactate dehydrogenase (pLDH), are useful epidemiological tools for rapid diagnostic test evaluation. This study presents the comparative evaluation of two multiplex platforms in identifying Plasmodium falciparum with presence or absence of HRP2/HRP3 expression as being indicative of hrp2/hrp3 deletions and other Plasmodium species. Moreover, correlation between the malaria antigen measurements performed at these platforms is assessed after calibrating with either assay standards or international standards and the cross-reactivity among Plasmodium species is examined.
A 77-member panel of specimens composed of the World Health Organization (WHO) international Plasmodium antigen standards, cultured parasites for P. falciparum and Plasmodium knowlesi, and clinical specimens with mono-infections for P. falciparum, Plasmodium vivax, and Plasmodium malariae was generated as both whole blood and dried blood spot (DBS) specimens. Assays for HRP2, P. falciparum-specific pLDH (PfLDH), P. vivax-specific pLDH (PvLDH), and all human Plasmodium species Pan malaria pLDH (PanLDH) on the Human Malaria Array Q-Plex and the xMAP platforms were evaluated with these panels.
The xMAP showed a higher percent positive agreement for identification of hrp2-deleted P. falciparum and Plasmodium species in whole blood and DBS than the Q-Plex. For whole blood samples, there was a highly positive correlation between the two platforms for PfLDH (Pearson r = 0.9926) and PvLDH (r = 0. 9792), moderate positive correlation for HRP2 (r = 0.7432), and poor correlation for PanLDH (r = 0.6139). In Pearson correlation analysis between the two platforms on the DBS, the same assays were r = 0.9828, r = 0.7679, r = 0.6432, and r = 0.8957, respectively. The xMAP HRP2 assay appeared to cross-react with HRP3, while the Q-Plex did not. The Q-Plex PfLDH assay cross-reacted with P. malariae, while the xMAP did not. For both platforms, P. knowlesi was detected on the PvLDH assay. The WHO international standards allowed normalization across both platforms on their HRP2, PfLDH, and PvLDH assays in whole blood and DBS.
Q-Plex and xMAP show good agreement for identification of P. falciparum mutants with hrp2/hrp3 deletions, and other Plasmodium species. Quantitative results from both platforms, normalized into international units for HRP2, PfLDH, and PvLDH, showed good agreement and should allow comparison and analysis of results generated by either platform.
同时检测疟原虫抗原(包括富组氨酸蛋白 2(HRP2)/HRP3 和疟原乳酸脱氢酶(pLDH)的免疫分析平台,是快速诊断测试评估的有用的流行病学工具。本研究介绍了两种多重平台在识别有或无 HRP2/HRP3 表达的恶性疟原虫的比较评估,HRP2/HRP3 表达表明 HRP2/HRP3 缺失和其他疟原虫种。此外,评估了在这些平台上进行的疟疾抗原测量之间的相关性,在使用检测标准或国际标准进行校准后,并检查了疟原虫种之间的交叉反应性。
使用世界卫生组织(WHO)国际疟原虫抗原标准、恶性疟原虫和疟原虫 knowlesi 的培养寄生虫以及恶性疟原虫、间日疟原虫和恶性疟原虫的单感染临床标本组成的 77 个成员的标本面板,生成全血和干血斑(DBS)标本。用人疟疾阵列 Q-Plex 和 xMAP 平台上的 HRP2、恶性疟原虫特异性 pLDH(PfLDH)、间日疟原虫特异性 pLDH(PvLDH)和所有人类疟原虫种泛疟原虫 pLDH(PanLDH)检测这些面板。
xMAP 对全血和 DBS 中 hrp2 缺失的恶性疟原虫和疟原虫种的阳性鉴定百分比高于 Q-Plex。对于全血样本,两个平台之间 PfLDH(Pearson r = 0.9926)和 PvLDH(r = 0.9792)具有高度正相关,HRP2(r = 0.7432)具有中度正相关,PanLDH(r = 0.6139)相关性较差。在 DBS 上两个平台之间的 Pearson 相关分析中,相同的检测 r = 0.9828、r = 0.7679、r = 0.6432 和 r = 0.8957。xMAP HRP2 检测似乎与 HRP3 发生交叉反应,而 Q-Plex 则没有。Q-Plex PfLDH 检测与恶性疟原虫发生交叉反应,而 xMAP 则没有。对于两个平台,在 PvLDH 检测中均检测到疟原虫 knowlesi。WHO 国际标准允许在全血和 DBS 中对其 HRP2、PfLDH 和 PvLDH 检测进行归一化。
Q-Plex 和 xMAP 对识别具有 HRP2/HRP3 缺失的恶性疟原虫突变体和其他疟原虫种具有良好的一致性。来自两个平台的定量结果,归一化为 HRP2、PfLDH 和 PvLDH 的国际单位,显示出良好的一致性,并且应该允许对任何一个平台生成的结果进行比较和分析。